Cargando…

Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective

The prevalence of Non-alcoholic fatty liver disease (NAFLD) and associated complications, such as hepatocellular carcinoma (HCC), is growing worldwide, due to the epidemics of metabolic risk factors, such as obesity and type II diabetes. Among other factors, an aberrant lipid metabolism represents a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Jian, Sigon, Giordano, Mullish, Benjamin H., Wang, Dan, Sharma, Rohini, Manousou, Pinelopi, Forlano, Roberta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143024/ https://www.ncbi.nlm.nih.gov/pubmed/37111211 http://dx.doi.org/10.3390/nu15081992

Ejemplares similares

Screening for NAFLD—Current Knowledge and Challenges
por: Forlano, Roberta, et al.
Publicado: (2023)

Gut Microbiota—A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review
por: Forlano, Roberta, et al.
Publicado: (2022)

The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease
por: Forlano, Roberta, et al.
Publicado: (2022)

Liver function tests and metabolic-associated fatty liver disease: Changes in upper normal limits, does it really matter?
por: Forlano, Roberta, et al.
Publicado: (2021)

Metabolic Profile Reflects Stages of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
por: Jambulingam, Nila, et al.
Publicado: (2023)

Non-alcoholic fatty liver disease in women – Current knowledge and emerging concepts
por: Eng, Pei Chia, et al.
Publicado: (2023)

THU642 Progression To Cirrhosis And All-cause Mortality Are Increased In Postmenopausal Women With NAFLD
por: Izzi-Engbeaya, Chioma, et al.
Publicado: (2023)

Current and future pharmacological therapies for managing cirrhosis and its complications
por: Kockerling, David, et al.
Publicado: (2019)

Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non‐alcoholic fatty liver disease; the importance of an elevated mean platelet volume
por: Abeles, Robin D., et al.
Publicado: (2019)

High-Throughput, Machine Learning–Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease
por: Forlano, Roberta, et al.
Publicado: (2020)

Lipidomics in non-alcoholic fatty liver disease
por: Kartsoli, Sofia, et al.
Publicado: (2020)

The effects of dietary supplementation with inulin and inulin‐propionate ester on hepatic steatosis in adults with non‐alcoholic fatty liver disease
por: Chambers, Edward S., et al.
Publicado: (2018)

The Effect of Mycotoxins and Silymarin on Liver Lipidome of Mice with Non-Alcoholic Fatty Liver Disease
por: Bechynska, Kamila, et al.
Publicado: (2021)

Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics
por: Riccio, Simona, et al.
Publicado: (2022)

Cancer surveillance in non-alcoholic fatty liver disease: A potential role for lipidomics
por: Best, Jan, et al.
Publicado: (2021)

In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19
por: Forlano, Roberta, et al.
Publicado: (2020)

Lipidomic Analysis of the Protective Effects of Shenling Baizhu San on Non-Alcoholic Fatty Liver Disease in Rats
por: Deng, Yuanjun, et al.
Publicado: (2019)

Nonalcoholic fatty liver disease stratification by liver lipidomics
por: Vvedenskaya, Olga, et al.
Publicado: (2021)

Lipidomics and Redox Lipidomics Indicate Early Stage Alcohol‐Induced Liver Damage
por: Koelmel, Jeremy P., et al.
Publicado: (2021)

The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma
por: Lewinska, Monika, et al.
Publicado: (2021)

Alterations in circulating lipidomic profile in patients with type 2 diabetes with or without non-alcoholic fatty liver disease
por: Alfadda, Assim A., et al.
Publicado: (2023)

Non-alcoholic fatty liver disease: the pathologist’s perspective
por: Leow, Wei-Qiang, et al.
Publicado: (2023)

Hepatic Lipidomics and Molecular Imaging in a Murine Non-Alcoholic Fatty Liver Disease Model: Insights into Molecular Mechanisms
por: Rodríguez-Calvo, Ricardo, et al.
Publicado: (2020)

Integrative lipidomic and transcriptomic study unravels the therapeutic effects of saikosaponins A and D on non-alcoholic fatty liver disease
por: Li, Xiaojiaoyang, et al.
Publicado: (2021)

The lipidome in nonalcoholic fatty liver disease: actionable targets
por: Pirola, Carlos J., et al.
Publicado: (2021)

Non-alcoholic fatty liver disease–From the cardiologist perspective
por: Sîrbu, Oana, et al.
Publicado: (2016)

Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study
por: Appleby, Richard N., et al.
Publicado: (2019)

Ultrasound/Elastography techniques, lipidomic and blood markers compared to Magnetic Resonance Imaging in non-alcoholic fatty liver disease adults
por: Cantero, Irene, et al.
Publicado: (2019)

Mapping Proteome and Lipidome Changes in Early-Onset Non-Alcoholic Fatty Liver Disease Using Hepatic 3D Spheroids
por: Frandsen, Helle Sedighi, et al.
Publicado: (2022)

Advances in paediatric nonalcoholic fatty liver disease: Role of lipidomics
por: Di Sessa, Anna, et al.
Publicado: (2021)

Perspectives on Interval Exercise Interventions for Non-Alcoholic Fatty Liver Disease
por: Hamasaki, Hidetaka
Publicado: (2019)

MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives
por: Hochreuter, Mette Yde, et al.
Publicado: (2022)

Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases
por: Sharma, Satya Priya, et al.
Publicado: (2021)

A New Targeted Lipidomics Approach Reveals Lipid Droplets in Liver, Muscle and Heart as a Repository for Diacylglycerol and Ceramide Species in Non-Alcoholic Fatty Liver
por: Preuss, Christina, et al.
Publicado: (2019)

Spatial Systems Lipidomics Reveals Nonalcoholic Fatty Liver Disease Heterogeneity
por: Ščupáková, Klára, et al.
Publicado: (2018)

Lipidomics analysis reveals new insights into the goose fatty liver formation
por: Wei, Rongxue, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease: an update on diagnosis
por: DUMITRASCU, DAN L., et al.
Publicado: (2018)

Lipidomics for the Prediction of Progressive Liver Disease in Patients with Alcohol Use Disorder
por: Gao, Bei, et al.
Publicado: (2022)

Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease
por: Mehta, Rohini, et al.
Publicado: (2016)

Pediatric non-alcoholic fatty liver disease: current perspectives on diagnosis and management
por: Di Sessa, Anna, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fmi3ocbvfs58jf624at5ncfo4u